Given the evidence indicating a deleterious role for the CB1 receptor in diabetic nephropathy, several studies have investigated the utility of CB1 antagonist/inverse agonists as a potential therapeutic option for diabetic kidney disease.15,20,24,46,47. Here, CNR1 is linked to diabetic kidney disease.